Kardium's Globe Mapping and Ablation System is intended to disrupt a roughly $6-billion market for treating atrial fibrillation, which is expected to grow by 15 per cent a year as Baby Boomers age.
The EU’s favourable polic, is creating advantages for Canadian firms like Kardium looking to expand globally amid the pandemic.
Early successes in roll-out of world’s most complete solution for atrial fibrillation
Medical device company gets certification for European sales.
Global-AF study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe System.
Financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders.
Kardium has raised an undisclosed amount in a new financing round.
Kardium hopes to receive marketing approval in Europe and launch its breakthrough Globe Mapping and Ablation System.
Study at Heart Rhythm 2018 shows very good efficacy in treating atrial fibrillation.
Burnaby-based medical technology maker Kardium Inc. is launching a device to treat atrial fibrillation in Europe.